A new report from Deloitte projects Canadians will create C$4.34 billion in sales of legal recreational cannabis product during 2019.

Deloitte’s latest cannabis market projection report released on Tuesday (June 5) indicates the entire Canadian cannabis market has the potential to reach close to C$7.2 billion by 2019.


As part of this report, the research firm surveyed cannabis consumers on their consumption trends and how that may change with the upcoming legalization of recreational cannabis in the country.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

According to the Canadian Press the results from an online survey of 1,500 Canadians, which took place between March 6-20, created the projection of C$4.34 billion for adult-use cannabis.

“Executed well, legalization will also help shift a considerable proportion of cannabis consumption to legal channels in the years to come,” Deloitte said.

In its conclusion Deloitte wrote the effect of legalization for cannabis in Canada, on its own, won’t move consumers to switch from illegal sources into legal government approved retailers. “[O]ur research suggests the right mix of quality, price and safety could just do the trick.”

Canadian licensed producers are working not only to develop the product needed for their sales projections but to entice consumers into joining legal avenues for the consumption of the drug, Allan Rewak, executive director of the Cannabis Canada Council, told the Investing News Network (INN).

During the Lift & Co Cannabis Expo in Toronto in late May, Rewak said a mission for the council, a grouping representing the interests of LPs, is to “migrate” consumers into the government approved market.

The study also found “current and likely consumers” are, at present, expecting to pay “slightly more” for legal products. On the things needed to really entice consumers away from illegal suppliers, Deloitte wrote:

High product quality and integrity (as affirmed by quality testing) as well as a range of competitive price points will be needed to persuade current consumers to move their purchases over to legal sources. Delivering a superior customer experience will be of vital importance.

Investor takeaway

The promise of the sales from the legalized adult-use market in Canada is starting to become a reality. Projections are closing in on the first year of sales and this latest one by Deloitte shows a high expectation of the growth the industry will see during 2019.

Don’t forget to follow us @INN_Cannabis for real-time news updates! Stay tuned to our cannabis channel for more stories from Lift.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Ayurcann Holdings Corp. (CSE: AYUR) (FSE:3ZQ0) (the “ Company ” or “ Ayurcann ”) a Canadian cannabis extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to announce that it has entered into a patient-referral agreement with The Herb Clinic (“ Clinic ”), providing Canadians guidance and access to managing discomfort with medicinal cannabis.

The Herb Clinic has over 4000 patients registered and is comprised of compassionate and knowledgeable service providers who are defined by their ability to provide exceptional patient care. They help educate and integrate cannabis into the patient’s medical treatment plans and partner with medicinal cannabis providers such as Ayurcann, to ensure their patients are getting top-quality advice with exceptional value.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today its “Summer of Social Justice” nationwide initiative raised over $250,000 for social justice-focused community organizations and supported the expungement process for over 1,000 individuals with cannabis-related criminal records.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005254/en/

Keep reading... Show less

A middling Canadian cannabis producer announced an executive turnover plan this week after receiving a critical investor letter in September.

Meanwhile, a Canadian exchange-traded fund (ETF) company released lists of new additions to both of its cannabis funds as part of its quarterly rebalancing.

Keep reading... Show less
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less